Exome Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.46M Buy
73,708
+51,291
+229% +$3.6M 2.92% 13
2026
Q2
$1.56M Buy
+22,417
New +$1.64M 0.97% 39
2025
Q2
– Sell
-148,830
Closed -$1.67M – 75
2025
Q1
$1.52M Buy
148,830
+107,618
+261% +$1.41M 1.35% 36
2024
Q4
$575K Buy
+41,212
New +$727K 0.43% 52

Other funds holding NKTR

Exome Asset Management's NKTR Position: Q3 2026 in Review

Exome Asset Management increased its Nektar Therapeutics (NKTR) stake by 229% in Q3 2026, buying an estimated $3.6M and bringing the position to 73,708 shares worth $4.46M. The position accounts for 2.92% of the portfolio, ranked #13.

Exome Asset Management first reported a position in NKTR in Q4 2024 and has held it in 4 quarters since. 242 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Exome Asset Management held 73,708 shares of Nektar Therapeutics worth $4.46M as of Q3 2026.
  • Exome Asset Management bought 51,291 Nektar Therapeutics shares in Q3 2026, an estimated $3.6M.
  • Nektar Therapeutics made up 2.92% of Exome Asset Management's portfolio in Q3 2026, its #13 holding.
  • Exome Asset Management first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 242 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Exome Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.